Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
So should be US and UK ex-entitlement next week and prices to converge somewhat again.
As we're already priced excluding Accustem I guess they'll come down to meet us, then we're free to move without complications. Clean slate on Monday and perfect time for that main market RNS!
Nothing ground breaking, just thought people may be interested
Public Title: Nasal administration of monoclonal anti-CD3 antibody (Foralumab¿) in the treatment of patients with moderate disease of SARS-CoV-2 infection (COVID-19).
Responsible Researcher: Rogerio Aparecido Dedivitis
Public Contact: Rogerio Aparecido Dedivitis
Health conditions or problems studied: Nasal administration of monoclonal anti-CD3 antibody;
treatment of patients with moderate sars-cov-2 infection disease (COVID-19)
ICD Descriptors - General: Coronavirus infection, not specified
ICD Descriptors - Specific: Coronavirus infection, not specified
ICD Descriptors - Intervention:
Cep/CONEP Ethical Approval Date: 10/23/2020
Name of the Institution: BROTHERHOOD OF THE HOLY HOUSE OF MISERICORDIA DE SANTOS
City: SANTOS
Might want to log in to check your shiny new shares!
Whimax - this is how I've reconciled the difference in prices and record dates in the US in my own mind.
Ordinary shares can usually be converted into ADR's by JP Morgan depending on supply and demand so will be a fluctuating number. As of the 28th October the register was closed so at the moment the US are trading ADR's between themselves with no more being issued or cancelled.
It has to be this way as you can't convert UK held shares to ADR's as they have already had Accustem shares allocated and they can't be allocated twice.
As of the 6th or 9th (not sure) JP Morgan will be free to issue or cancel ADR's again and we'll be back to parity with the US.
'Covering head, waiting to be shot down'
Not gonna lie, shine has been taken off it but nothing a beer or two won't fix.
See you all Monday I guess....
"Shareholders are reminded that unless the counterparties specifically agree otherwise, a buyer of the Company's Ordinary Shares ahead of the Ex-Date will assume the benefit to the Demerged Shares, and a seller, ahead of the Ex-Date, would need to pass the benefit to the buyer, even if the seller is the recorded owner at the Record Date."
EVEN IF THE SELLER IS THE RECORDED OWNER AT THE RECORD DATE
Sorry for SHOUTING, can't figure out how to underline.
Right, so Friday at 4:30 it is then.
Bit of a bargain today at this price!
LJ - gotta be Friday or Monday once we're clear of demerger process?
Kunwar's sitting in his armchair with a whiskey polishing that golden RNS!
Is it possible to tell how many of the 194million shares are held in ADR's?
Appreciate it changes but wondering which side of the Atlantic holds more.
I'm getting flashbacks to the change in ADS ratio in July.
Luckily for us all the quality of the science far outweighs the admin!
Cheers Olds,
Hoping they hit the ground running with Accustem. Be nice to get this week done and dusted and let both companies begin to reach their full potential.
Anyone know how we'll receive updates about Accustem after demerger and before it lists?
Will it be continue to be through TILS RNS' until Accustem can issue their own?
Is one of you lot GeorgeMoney on Stockwits? Almost spat my tea out reading his posts. LOL
Usain - Yep we know of at least 2 RNS' ready to drop and the BOD have been working towards this moment for at least 6 months so they have a plan. Each to their own, but anywhere in the high 100's or low 200's next week I'm just letting it all ride.
Were people aware Kunwar has now been added as a Director of Accustem? Won't take any credit, was just trawling Twitter
Nice for an RNS just after demerger. I'm more than OK with that
Thanks BMO3, was just looking through your post from this morning to get dial in details... so 9:15pm UK time.
Hoping for more info on Brazil trial. Been trawling a number of Clinical Trial websites today trying to find our Foralumab Brazil trial but no luck. May be a lag before they get registered on these sites.
The National Institutes of Health (Primary Agency of US Government for Clinical Research) has launched a clinical trial to evaluate the safety of three immune modulator drugs in hospitalized adults with COVID-19
https://www.nih.gov/news-events/news-releases/nih-begins-large-clinical-trial-test-immune-modulators-treatment-covid-19
Like Foralumab and TZLS501 these are designed to modulate the bodies immune response to the Covid infection rather than fight the virus directly. To me this validates the approach Tiziana are taking in the Brazil trial.
Drugs in trial:
Infliximab - Injectable Chimeric Monoclonal Antibody (non human) with recognised side effects
Abatacept - IV or injection T cell regulator. Serious side effects including slow growing cancers to proliferate and death (according to Wikipedia)
Cenicriviroc - Orally administered. Prevents virus from entering cells and with possible anti-inflammatory effect
Why is Forulamab not one of the 3 being evaluated? Due to the size of Tiziana I don't believe we can fulfil one of the criteria which is to have the availability for large scale clinical studies. Genuinely exciting times to be invested in this company and you can bet interested parties will be keeping a very close eye on this Brazil trial.